Beam Therapeutics Inc [NASDAQ: BEAM] jumped around 1.16 points on Wednesday, while shares priced at $21.46 at the close of the session, up 5.71%.
Beam Therapeutics Inc stock is now -7.02% down from its year-to-date (YTD) trading value. BEAM Stock saw the intraday high of $22.39 and lowest of $20.8575 per share. The company’s 52-week high price is 35.25, which means current price is +58.67% above from all time high which was touched on 02/18/25.
Compared to the average trading volume of 2.07M shares, BEAM reached a trading volume of 3947609 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Beam Therapeutics Inc [BEAM]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BEAM shares is $43.44 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BEAM stock is a recommendation set at 1.39. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for Beam Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 28, 2025. The new note on the price target was released on March 10, 2025, representing the official price target for Beam Therapeutics Inc stock. On November 06, 2024, analysts increased their price target for BEAM shares from 27 to 39.
The Price to Book ratio for the last quarter was 1.92, with the Price to Cash per share for the same quarter was set at 12.13.
How has BEAM stock performed recently?
Beam Therapeutics Inc [BEAM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 22.42. With this latest performance, BEAM shares gained by 15.53% in over the last four-week period, additionally sinking by -15.45% over the last 6 months – not to mention a drop of -13.47% in the past year of trading.
Beam Therapeutics Inc [BEAM]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Beam Therapeutics Inc [BEAM] shares currently have an operating margin of -677.47% and a Gross Margin at 65.36%. Beam Therapeutics Inc’s Net Margin is presently recorded at -609.24%.
Return on Equity for this stock declined to -27.41%, with Return on Assets sitting at -27.41%.
Earnings analysis for Beam Therapeutics Inc [BEAM]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BEAM. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Beam Therapeutics Inc go to -0.84%.
Insider trade positions for Beam Therapeutics Inc [BEAM]
There are presently around $98.07%, or 99.28% of BEAM stock, in the hands of institutional investors. The top three institutional holders of BEAM stocks are: FARALLON CAPITAL MANAGEMENT LLC with ownership of 7.91 million shares, which is approximately 9.6135%. VANGUARD GROUP INC, holding 7.9 million shares of the stock with an approximate value of $$185.11 million in BEAM stocks shares; and VANGUARD GROUP INC, currently with $$178.87 million in BEAM stock with ownership which is approximately 9.2749%.
